TY - JOUR
T1 - Dosis de refuerzo con la vacuna BNT162b2 en población que recibió el esquema de vacunación completa para COVID-19 en Perú
T2 - Un análisis crítico de la evidencia actual
AU - Toro-Huamanchumo, Carlos J.
AU - Zavala-Loayza, Jose A.
AU - Martinez-Rivera, Raisa N.
AU - Peralta, Verónica
AU - Peña-Sanchez, Eric R.
N1 - Publisher Copyright:
© 2021 Medical Body of the Almanzor Aguinaga Asenjo National Hospital. All Rights Reserved.
PY - 2021/10/21
Y1 - 2021/10/21
N2 - Background: In Peru, the current immunization schedule for COVID-19 includes BBIBP-CorV, BNT162B2 and ChAdOx1 nCoV-19 vaccines. Although the full immunization schedule is two doses, some countries have recently included a booster dose to their schedule. Methods: We conducted a search for scientific evidence on the efficacy and safety of booster vaccination with BNT162b2 vaccine in a population with a complete vaccination schedule for COVID-19 in Peru. Ev idence: Four evidence-based recommendation documents, one observational study and three ongoing phase III clinical trials were included for analysis. Conclusion: To date, there is insufficient evidence on the efficacy of adding a booster dose to the immunization schedule for COVID-19. The available evidence does not justify the use of a booster dose of BNT162B2 vaccine in a population that has previously received two doses of the aforementioned vaccines.
AB - Background: In Peru, the current immunization schedule for COVID-19 includes BBIBP-CorV, BNT162B2 and ChAdOx1 nCoV-19 vaccines. Although the full immunization schedule is two doses, some countries have recently included a booster dose to their schedule. Methods: We conducted a search for scientific evidence on the efficacy and safety of booster vaccination with BNT162b2 vaccine in a population with a complete vaccination schedule for COVID-19 in Peru. Ev idence: Four evidence-based recommendation documents, one observational study and three ongoing phase III clinical trials were included for analysis. Conclusion: To date, there is insufficient evidence on the efficacy of adding a booster dose to the immunization schedule for COVID-19. The available evidence does not justify the use of a booster dose of BNT162B2 vaccine in a population that has previously received two doses of the aforementioned vaccines.
KW - COVID-19 Vaccines
KW - Coronavirus Infections
KW - Immunization, Secondary
UR - http://www.scopus.com/inward/record.url?scp=85119193959&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/122d19bf-9242-3a45-bff7-4a07c33c1227/
U2 - 10.35434/rcmhnaaa.2021.14Sup1.1177
DO - 10.35434/rcmhnaaa.2021.14Sup1.1177
M3 - Artículo
AN - SCOPUS:85119193959
SN - 2225-5109
VL - 14
SP - 70
EP - 78
JO - Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
JF - Revista del Cuerpo Medico Hospital Nacional Almanzor Aguinaga Asenjo
ER -